|
| Target gene | Validation | Gene description | Number of miRNA |
| Healthy control versus LS | Healthy controls versus CXR III-IV | LS versus CXR III-IV |
|
| ACVR1 | V | Activin A receptor, type I | 0 | 0 | 1 |
| ACVR1C | V | Activin A receptor, type IC | 0 | 0 | 1 |
| ACVR2A | V | Activin A receptor, type IIA | 0 | 0 | 1 |
| ACVR2B | V | Activin A receptor, type IIB | 0 | 0 | 3 |
| AKT3 | V | v-akt murine thymoma viral oncogene homolog 3 | 2 | 3 | 0 |
| APC | V | Adenomatous polyposis coli | 0 | 1 | 0 |
| APPL1 | V | Adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 | 2 | 1 | 0 |
| ARNT | V | Aryl hydrocarbon receptor nuclear translocator | 1 | 3 | 0 |
| AXIN2 | V | Axin 2 | 1 | 1 | 0 |
| BCL2 | V | B-cell CLL/lymphoma 2 | 3 | 3 | 0 |
| BCR | V | Breakpoint cluster region | 2 | 2 | 0 |
| BMPR2 | V | Bone morphogenetic protein receptor, type II (serine/threonine kinase) | 0 | 0 | 2 |
| BRCA2 | V | Breast cancer 2, early onset | 1 | 1 | 0 |
| CASP8 | V | Caspase 8, apoptosis-related cysteine peptidase | 1 | 1 | 0 |
| CBL | V | Cbl proto-oncogene, E3 ubiquitin protein ligase | 1 | 3 | 0 |
| CCDC6 | V | Coiled-coil domain containing 6 | 2 | 2 | 0 |
| CCND1 | V | Cyclin D1 | 2 | 3 | 0 |
| CCNE1 | V | Cyclin E1 | 1 | 2 | 0 |
| CDC42 | V | Cell division cycle 42 | 1 | 2 | 0 |
| CDK6 | V | Cyclin-dependent kinase 6 | 4 | 4 | 0 |
| CDKN1A | V | Cyclin-dependent kinase inhibitor 1A (p21, Cip1) | 2 | 2 | 0 |
| COL4A1 | V | Collagen, type IV, alpha 1 | 2 | 1 | 0 |
| COL4A4 | V | Collagen, type IV, alpha 4 | | 1 | 0 |
| CRK | V | v-crk avian sarcoma virus CT10 oncogene homolog | 1 | 3 | 0 |
| CRKL | V | v-crk avian sarcoma virus CT10 oncogene homolog-like | 1 | 1 | 0 |
| CTBP2 | V | C-terminal binding protein 2 | 0 | 1 | 0 |
| CTNNB1 | V | Catenin (cadherin-associated protein), beta 1, 88 kDa | 1 | 1 | 0 |
| CUL2 | V | Cullin 2 | 1 | 1 | 0 |
| CYCS | V | Cytochrome c, somatic | 1 | 1 | 0 |
| DVL1 | V | Dishevelled segment polarity protein 1 | 1 | 1 | 0 |
| E2F1 | V | E2F transcription factor 1 | 2 | 1 | 0 |
| E2F2 | V | E2F transcription factor 2 | 1 | 1 | 0 |
| E2F3 | V | E2F transcription factor 3 | 3 | 3 | 0 |
| E2F5 | V | E2F transcription factor 5, p130-binding | 0 | 0 | 1 |
| EGLN1 | V | egl-9 family hypoxia-inducible factor 1 | 1 | 1 | 0 |
| EGLN2 | V | egl-9 family hypoxia-inducible factor 2 | 1 | 1 | 0 |
| EGLN3 | V | egl-9 family hypoxia-inducible factor 3 | 1 | 1 | 0 |
| EP300 | V | E1A binding protein p300 | | 2 | 1 |
| EPAS1 | V | endothelial PAS domain protein 1 | 2 | 1 | 0 |
| ETS1 | V | v-ets avian erythroblastosis virus E26 oncogene homolog 1 | 0 | 1 | 0 |
| FADD | V | Fas (TNFRSF6)-associated via death domain | 1 | 1 | 0 |
| FAS | V | Fas cell surface death receptor | 2 | 1 | 0 |
| FASLG | V | Fas ligand (TNF superfamily, member 6) | 1 | 0 | 0 |
| FGF1 | V | Fibroblast growth factor 1 (acidic) | 1 | 0 | 0 |
| FGF13 | V | Fibroblast growth factor 13 | 1 | 0 | 0 |
| FGF14 | V | fibroblast growth Factor 14 | 0 | 1 | 0 |
| FGF2 | V | Fibroblast growth factor 2 (basic) | 1 | 1 | 0 |
| FGF4 | V | Fibroblast growth factor 4 | 1 | 1 | 0 |
| FGF7 | V | Fibroblast growth factor 7 | 3 | 3 | 0 |
| FGF9 | V | Fibroblast growth factor 9 | 1 | 1 | 0 |
| FGFR1 | V | Fibroblast growth factor receptor 1 | 1 | 1 | 0 |
| FGFR2 | V | Fibroblast growth factor receptor 2 | 1 | 1 | 0 |
| FIGF | V | c-fos induced growth factor (vascular endothelial growth factor D) | 1 | 1 | 0 |
| FLT3 | V | fms-related tyrosine kinase 3 | 1 | 1 | 0 |
| FN1 | V | Fibronectin 1 | | 1 | 0 |
| FOXO1 | V | Forkhead box O1 | 1 | 1 | 0 |
| FZD1 | V | Frizzled family receptor 1 | 1 | 1 | 0 |
| FZD10 | V | Frizzled family receptor 10 | 1 | 1 | 0 |
| FZD4 | V | Frizzled family receptor 4 | 0 | 1 | 0 |
| FZD7 | V | Frizzled family receptor 7 | 0 | 1 | 0 |
| GDF5 | V | Growth differentiation factor 5 | 0 | 0 | 1 |
| GRB2 | V | Growth factor receptor-bound protein 2 | 1 | 1 | 0 |
| HHIP | V | Hedgehog interacting protein | 0 | 1 | 0 |
| HIF1A | V | Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | 1 | 1 | 0 |
| HSP90B1 | V | Heat shock protein 90 kDa beta (Grp94), member 1 | 0 | 2 | 0 |
| CHUK | V | Conserved helix-loop-helix ubiquitous kinase | 1 | 1 | 0 |
| IGF1 | V | Insulin-like growth factor 1 (somatomedin C) | 2 | 2 | 0 |
| IGF1R | V | Insulin-like growth factor 1 receptor | 1 | 1 | 0 |
| IKBKB | V | Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta | 1 | 2 | 0 |
| IL8 | V | Interleukin 8 | 1 | 1 | 0 |
| ITGA2 | V | Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) | 1 | 1 | 0 |
| ITGA3 | V | Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) | 0 | 1 | 0 |
| ITGA6 | V | Integrin, alpha 6 | 1 | 0 | 0 |
| ITGAV | V | Integrin, alpha V | 1 | 0 | 0 |
| JAK1 | V | Janus kinase 1 | 2 | 1 | 0 |
| JUN | V | Jun proto-oncogene | 1 | 1 | 0 |
| KRAS | V | Kirsten rat sarcoma viral oncogene homolog | 1 | 3 | 0 |
| LAMA3 | V | Laminin, alpha 3 | 1 | 1 | 0 |
| LAMC1 | V | Laminin, gamma 1 (formerly LAMB2) | 2 | 2 | 0 |
| LAMC2 | V | Laminin, gamma 2 | 0 | 2 | 0 |
| LTBP1 | V | Latent transforming growth factor beta binding protein 1 | 0 | 0 | 1 |
| MAP2K1 | V | Mitogen-activated protein kinase kinase 1 | 1 | 1 | 0 |
| MAPK1 | V | Mitogen-activated protein kinase 1 | 1 | 3 | 1 |
| MAPK10 | V | Mitogen-activated protein kinase 10 | 1 | 0 | 0 |
| MAPK3 | V | Mitogen-activated protein kinase 3 | 0 | 1 | 0 |
| MAPK9 | V | Mitogen-activated protein kinase 9 | 2 | 3 | 0 |
| MET | V | Met proto-oncogene | 0 | 1 | 0 |
| MITF | V | Microphthalmia-associated transcription factor | 1 | 0 | 0 |
| MMP2 | V | Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase) | 1 | 1 | 0 |
| MSH2 | V | mutS homolog 2 | 2 | 1 | 0 |
| NRAS | V | Neuroblastoma RAS viral (v-ras) oncogene homolog | 1 | 1 | 0 |
| PDGFA | V | Platelet-derived growth factor alpha polypeptide | 0 | 1 | 0 |
| PDGFRA | V | Platelet-derived growth factor receptor, alpha polypeptide | 2 | 1 | 0 |
| PIAS1 | V | Protein inhibitor of activated STAT, 1 | 1 | 1 | 0 |
| PIAS3 | V | Protein inhibitor of activated STAT, 3 | 0 | 1 | 0 |
| PIK3R1 | V | Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | 3 | 4 | 0 |
| PIK3R3 | V | Phosphoinositide-3-kinase, regulatory subunit 3 (gamma) | 1 | 2 | 0 |
| PITX2 | V | Paired-like homeodomain 2 | 0 | 0 | 1 |
| PPP2CB | V | Protein phosphatase 2, catalytic subunit, beta isozyme | 0 | 0 | 1 |
| PRKCA | V | Protein kinase C, alpha | 1 | 1 | 0 |
| PTEN | V | Phosphatase and tensin homolog | 2 | 1 | 0 |
| PTCH1 | V | Patched 1 | 1 | 2 | 0 |
| RAC1 | V | Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) | 1 | 0 | 0 |
| RAF1 | V | v-raf-1 murine leukemia viral oncogene homolog 1 | 1 | 1 | 0 |
| RALA | V | v-ral simian leukemia viral oncogene homolog A (ras related) | 0 | 1 | 0 |
| RALBP1 | V | ralA binding protein 1 | 2 | 1 | 0 |
| RARB | V | Retinoic acid receptor, beta | 2 | 3 | 0 |
| RASSF5 | V | Ras association (RalGDS/AF-6) domain family member 5 | 1 | 1 | 0 |
| RB1 | V | Retinoblastoma 1 | 1 | 2 | 0 |
| RET | V | Ret proto-oncogene | 1 | 1 | 0 |
| RHOA | V | Ras homolog family member A | 1 | 0 | 1 |
| ROCK1 | V | Rho-associated, coiled-coil containing protein kinase 1 | 0 | 0 | 1 |
| RPS6KB1 | V | Ribosomal protein S6 kinase, 70 kDa, polypeptide 1 | 0 | 0 | 1 |
| RUNX1 | V | Runt-related transcription factor 1 | 1 | 2 | 0 |
| RUNX1T1 | V | Runt-related transcription factor 1; translocated to, 1 (cyclin D-related) | 3 | 2 | 0 |
| SLC2A1 | V | Solute carrier family 2 (facilitated glucose transporter), member 1 | 0 | 2 | 0 |
| SMAD2 | V | SMAD family member 2 | 2 | 2 | 2 |
| SMAD3 | V | SMAD family member 3 | 1 | 1 | 0 |
| SMAD4 | V | SMAD family member 4 | 1 | 1 | 0 |
| SMAD5 | V | SMAD family member 5 | 0 | 0 | 1 |
| SMAD7 | V | SMAD family member 7 | 0 | 0 | 1 |
| SMURF1 | V | SMAD specific E3 ubiquitin protein ligase 1 | 0 | 0 | 1 |
| STAT1 | V | Signal transducer and activator of transcription 1, 91 kDa | 1 | 1 | 0 |
| STAT3 | V | Signal transducer and activator of transcription 3 (acute-phase response factor) | 2 | 1 | 0 |
| STK4 | V | Serine/threonine kinase 4 | | 1 | 0 |
| TCF7 | V | Transcription factor 7 (T-cell specific, HMG-box) | 1 | 1 | 0 |
| TCF7L1 | V | Transcription factor 7-like 1 (T-cell specific, HMG-box) | 2 | 2 | 0 |
| TCF7L2 | V | Transcription factor 7-like 2 (T-cell specific, HMG-box) | 0 | 1 | 0 |
| TFDP1 | V | Transcription factor Dp-1 | 0 | 0 | 1 |
| TGFB1 | V | Transforming growth factor, beta 1 | 1 | 0 | 1 |
| TGFBR1 | V | Transforming growth factor, beta receptor 1 | 1 | 0 | 1 |
| TGFBR2 | V | Transforming growth factor, beta receptor II (70/80 kDa) | 2 | 1 | 1 |
| THBS1 | V | Thrombospondin 1 | 0 | 0 | 1 |
| TPM3 | V | Tropomyosin 3 | 1 | 2 | 0 |
| TRAF6 | V | TNF receptor-associated factor 6, E3 ubiquitin protein ligase | 1 | 1 | 0 |
| VEGFA | V | Vascular endothelial growth factor A | 2 | 3 | 0 |
| VHL | V | Von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase | 1 | 1 | 0 |
| WNT11 | V | Wingless-type MMTV integration site family, member 11 | 1 | 0 | 0 |
| WNT3A | V | Wingless-type MMTV integration site family, member 3A | 1 | 1 | 0 |
| WNT7A | V | Wingless-type MMTV integration site family, member 7A | 1 | 1 | 0 |
| XIAP | V | X-linked inhibitor of apoptosis | 1 | 1 | 0 |
| ZFYVE16 | V | Zinc finger, FYVE domain containing 16 | 0 | 0 | 2 |
|
